XML 48 R38.htm IDEA: XBRL DOCUMENT v3.10.0.1

Commitments and Contingencies - Additional Information (Detail)		6 Months Ended
	May 24, 2018 USD ($)	Jun. 30, 2018 USD ($)	Jun. 30, 2018 GBP (£)
Further Indication for AMR101 | Marketing Approval In Europe
Commitments And Contingencies Disclosure [Line Items]
Potential aggregate stock or cash payment		$ 9,900,000	£ 7,500,000
Further Indication for AMR101 | Potential Marketing Approval 1
Commitments And Contingencies Disclosure [Line Items]
Potential aggregate stock or cash payment		6,600,000	5,000,000
Further Indication for AMR101 | Potential Marketing Approval 2
Commitments And Contingencies Disclosure [Line Items]
Potential aggregate stock or cash payment		6,600,000	5,000,000
Further Indication for AMR101 | Maximum
Commitments And Contingencies Disclosure [Line Items]
Potential aggregate stock or cash payment		13,200,000	£ 10,000,000
Nisshin
Commitments And Contingencies Disclosure [Line Items]
Royalty, milestone or minimum purchase commitments		$ 0
Teva
Commitments And Contingencies Disclosure [Line Items]
Payment made to Teva	$ 2,000,000

X

- Definition

Commitments and contingencies disclosure.

+ References

No definition available.

+ Details

Name:	amrn_CommitmentsAndContingenciesDisclosureLineItems
Namespace Prefix:	amrn_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Royalty, milestone or minimum purchase commitments.

+ References

No definition available.

+ Details

Name:	amrn_RoyaltyMilestoneOrMinimumPurchaseCommitments
Namespace Prefix:	amrn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Amount awarded to other party in judgment or settlement of litigation.

+ References

No definition available.

+ Details

Name:	us-gaap_LitigationSettlementAmountAwardedToOtherParty
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

The amount the entity has committed to make for future royalty guarantees.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 928
-SubTopic 440
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6473578&loc=d3e63223-108013

+ Details

Name:	us-gaap_RoyaltyGuaranteesCommitmentsAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Details

Name:	us-gaap_StatementScenarioAxis=amrn_FurtherIndicationForAMROneZeroOneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	amrn_BusinessDevelopmentsAxis=amrn_MarketingApprovalInEuropeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	amrn_BusinessDevelopmentsAxis=amrn_PotentialMarketingApprovalOneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	amrn_BusinessDevelopmentsAxis=amrn_PotentialMarketingApprovalTwoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=amrn_NisshinPharmaIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	dei_LegalEntityAxis=amrn_TevaPharmaceuticalsUSAIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: